Cargando…
Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature
Several cyclin‐dependent kinase 4/6 (CDK4/6) inhibitors are indicated in the treatment of metastatic hormone receptor‐positive (HR)/ human epidermal growth factor receptor 2 (HER2) negative breast cancer which includes palbociclib, ribociclib and abemaciclib. Pelvic radiation therapy (RT) is often i...
Autores principales: | Dasgupta, Archya, Sahgal, Arjun, Warner, Ellen, Czarnota, Gregory J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890927/ https://www.ncbi.nlm.nih.gov/pubmed/32985794 http://dx.doi.org/10.1002/jmrs.435 |
Ejemplares similares
-
Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021) -
Combination of palbociclib and radiotherapy for glioblastoma
por: Whittaker, Shane, et al.
Publicado: (2017) -
MRI texture features from tumor core and margin in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
por: Kolios, Christopher, et al.
Publicado: (2021) -
Quantitative ultrasound radiomics in predicting recurrence for patients with node‐positive head‐neck squamous cell carcinoma treated with radical radiotherapy
por: Dasgupta, Archya, et al.
Publicado: (2020) -
Ultrasound delta-radiomics during radiotherapy to predict recurrence in patients with head and neck squamous cell carcinoma
por: Fatima, Kashuf, et al.
Publicado: (2021)